A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have Type 2 diabetes
Have been on stable diabetes treatment with metformin 90 days before study start through randomization
Have not lost or gained body weight for at least 90 days prior to baseline and agree to not start an intensive diet or exercise program during the study with the intent to lose body weight other than lifestyle and/or dietary measures for diabetes treatment
Participants Must Not:
Have Type 1 Diabetes
Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to baseline
Have had congestive heart failure
Have had heart attack, stroke or hospitalized for congestive heart failure
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo